Juniper Pharmaceuticals Inc  

(Public, NASDAQ:JNP)   Watch this stock  
Find more results for NASDAQ:CBRX
4.90
-0.05 (-1.01%)
After Hours: 4.90 0.00 (0.00%)
Jul 21, 4:11PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.90 - 5.22
52 week 3.65 - 8.00
Open 4.90
Vol / Avg. 47,842.00/25,072.00
Mkt cap 51.57M
P/E 9.14
Div/yield     -
EPS 0.54
Shares 10.84M
Beta 0.29
Inst. own 37%
Aug 2, 2017
Q2 2017 Juniper Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 27, 2017
Juniper Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 4, 2017
Q1 2017 Juniper Pharmaceuticals Inc Earnings Release
May 4, 2017
Q1 2017 Juniper Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -12.81% 10.90%
Operating margin -12.94% 9.67%
EBITD margin - 13.15%
Return on average assets -10.11% 11.01%
Return on average equity -14.70% 15.53%
Employees 139 -
CDP Score - -

Address

33 Arch St Ste 3110
BOSTON, MA 02110-1424
United States - Map
+1-617-6391500 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

Officers and directors

James A. Geraghty Independence Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Alicia Secor Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Jeffrey E. Young Senior Vice President, Finance, Chief Financial Officer, Treasurer and Secretary (Principal Financial and Accounting Officer)
Age: 43
Bio & Compensation  - Reuters
Nikin Patel Chief Operating Officer, Director
Age: 44
Bio & Compensation  - Reuters
Bridget A. Martell Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Frank Murdoch Armstrong Independent Director
Age: 60
Bio & Compensation  - Reuters
Cristina Csimma Pharm.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Ann Merrifield Independent Director
Age: 66
Bio & Compensation  - Reuters